Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The October 2022 Transparency Commission considers that VYEPTI (eptinezumab) is a treatment option for patients suffering from severe migraine with at least 8 migraine days per month, who have failed at least two prophylactic treatments and have no cardiovascular impairment.
Since the beginning of 2023, eptinezumab has been available in France as an inpatient treatment prescribed by a migraine neurologist in a growing number of centres. The Saint-Denis Hospital and the Nîmes University Hospital are among the first centres to have started. The investigators from these 2 centres have therefore decided to pool their data to provide the first French feedback on its effectiveness.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Migraine patients | Patients with severe migraine, with at least 8 migraine days per month and at least 2 failed background treatments. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| None, pure observationnal study | Other | Pure observatonnal study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Headaches and migraines per month | Number of headache and migraine days per month. | 6 months |
| Responders | Rate of responders (30%, 50% and super responders > 75%) | 6 months |
| Duration | Duration of effect of eptinezumab infusion (Numbers of weeks) | 6 months |
| HIT6 scores (disability score) | Evaluation of HIT6 scores (disability score), ≤ 49 headaches have little impact on daily life; between 50 and 55: headaches have some impact on daily life; 56 to 59: headaches have a significant impact on daily life; ≥ 60 | 6 months |
| HAD (anxiety/depression score) | Evaluation of HAD score. From 0 to 7: absence of anxiety and/or depressive disorders, from 8 to 10: doubtful symptomatology, 11 to 21: proven anxiety and/or depression disorders of varying severity. | 6 months |
| Concomitant treatments | Use of concomitant crisis and background treatments (description) | 6 months |
Not provided
Not provided
Inclusion Criteria:
Adult patients suffering from severe migraine with at least 8 migraine days per month
Exclusion Criteria:
Not provided
Not provided
Not provided
Consecutive patients with severe migraine with at least 8 migraine days per month and failure of at least 2 disease-modifying therapies, treated with quarterly infusions of eptinezumab since March 2023 in a day hospital at the Saint-Denis hospital and the Nîmes university hospital.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anissa MEGZARI | Centre Hospitalier Universitaire de Nīmes | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nîmes | Nîmes | 30900 | France | |||
| CH de Saint Denis |
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Saint-Denis |
| 93200 |
| France |
| D009422 | Nervous System Diseases |